/
We have obtained the market data from certain publicly available sources of information, including publicly available independent industry publications and other third-party sources. We believe the data that third parties have compiled is reliable, but we have not independently verified the iii accuracy of this information and there is no assurance that any of the forecasted amounts will be ach…
$5.91
+$0.10 (+1.64%)
Live · 06:13 PM
The business is unprofitable at the operating level (-21.86% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 26.6% YoY. Margins deteriorated 20.3pp alongside, both lines moving the wrong way.
ROIC dropped from -1.87% to -20.77%, capital efficiency is deteriorating. Operating margin contracted 20.3pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.89B
▼ -26.6% YoY
Net Income (TTM)
-$497M
▼ -767.4% YoY
Op. Margin
-22.19%
▼ -20.3pp YoY
ROIC
-20.50%
▼ -18.9pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$33M
▲ +107.0% YoY
Net Debt
$843M
Cash & Equiv.
$142M
5Y CAGR: +15.2%
Continue Research
Evolent Health (EVH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Evolent Health scores 11/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Evolent Health scores 11 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -22.2% operating margin and a -20.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh EVH's valuation and scores 11/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.